State Enterprise “Nizhny Novgorod Regional Pharmacy” (SE “NOF”) and the Chinese corporation Guangdong Shuanglin Bio-pharmacy Co., Ltd. have signed a memorandum of cooperation. The document involves the creation of a joint local production of biological products from blood plasma in the Nizhny Novgorod Region. The signing ceremony took place on April 9, 2026, in the city of Zhanjiang (PRC). This is reported by the press service of SE “NOF”.
Technology Transfer and Product Range
The agreement provides for the transfer of plasma fractionation technologies to the Russian side under an exclusive license. The expertise of the Shuanglin corporation will ensure compliance of production processes with international quality standards.
At the first stage of cooperation, it is planned to launch the production of the following drugs:
- albumin;
- prothrombin complex;
- human immunoglobulin (normal and anti-rabies).
These components, obtained from donor blood, are used in emergency medical care and the treatment of a number of diseases. In the near future, the parties will begin preparing production sites and specialized training of personnel.
Integration into Regional Infrastructure
The document was signed by Pavel Yastrebov, General Director of SE “NOF”, and Yan Chen, General Director of the Chinese company. According to the head of the Nizhny Novgorod enterprise, the implementation of the agreement is the initial stage in the formation of a biopharmaceutical cluster in the region.
The production cycle of new medicines will be integrated into the existing infrastructure of the regional pharmacy. The localization of production is aimed at providing medical institutions in the region with their own products and reducing dependence on imported blood plasma products.
Regional Development Strategy
Cooperation with the Chinese side is carried out within the framework of a roadmap for the modernization of pharmaceutical production approved by the Governor of the Nizhny Novgorod Region.
In parallel with the preparation for the plasma fractionation project, other investment initiatives are being implemented in the region. In particular, the construction of two new pharmaceutical plants is planned in the “Kulibin” special economic zone. The declared investment volume in these production sites is estimated at 6 billion rubles.
